Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry

Rheumatology

Volumn 46, Issue 8, 2007, Pages 1345-1354

  Brennan, A ^a,d   Bansback, N ^a,b,d   Nixon, R ^c,d   Madan, J ^a   Harrison, M ^d   Watson, K ^d   Symmons, D ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ST PAUL S HOSPITAL   (Canada)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti TNF; Cost; Cost effectiveness; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONSULTATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; NATIONAL HEALTH SERVICE; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; REGISTER; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SHORT FORM 36; SIMULATION; TREATMENT OUTCOME; UNITED KINGDOM; VALIDATION PROCESS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG COSTS; EPIDEMIOLOGIC METHODS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547839821     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem115     Document Type: Article

References (66)

1. Symmons D, Turner G, Webb R et al. The prevalence of rheumatoid arthritis in the United Kingdom: New estimates for a new century. Rheumatology 2002;41:793.
2. Yelin E, Callahan LF. for the National Arthritis Data Work Group. The economic cost and social psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-6.
3. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: Joint destruction, disability, and early mortality. Br J Rheumatol 1993;32:28-37.
4. Wolfe F, Michaud K, Gefeller O et al. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
5. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9.
6. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
7. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
8. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
9. Bathon JM, Martin RW, Flaischmann RM et al. A comparison of etanercept and methotrexate in patients with earty rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
10. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004;363:675-81.
11. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet 1999;354:1932-9.
12. St Clair EWS, van der Heijde DMFM, Smolon JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
13. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003;48:35-45.
14. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-oontrolled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
15. van cle Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
16. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous mothotrexate treatment. Arthritis Rheum 2006;54:26-37.
17. Michaud K, Messer J, Choi HK et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: A three-year study of 7527 patients. Arthritis Rheum 2003;48:2750-62.
18. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation. Health Technol Assess 2002;6:1-110.
19. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
20. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: The case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:iIi, 1-91.
21. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
22. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: A systematic review and economic analysis. Health Technol Assess 2004;8:iIi-iv, ix-x, 1-105.
23. Choi HK, Seeger JD, Kuntz KIM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-27.
24. Rubio-Terres C, Dominguez-Gil A. Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with leflunomide in comparison with the combination of infliximab and methotrexate. J Drug Assess 2001;4:39-54.
25. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-65.
26. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
27. Kobelt G, Eberhardt K, Geborek P. TNF antagonists in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
28. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
29. Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-73.
30. Maetzel A. Cost-effectiveness analysis: Out of touch with clinical reality? Arthritis Care Res 2005;53:3-4.
31. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology 2004;43:4-6.
32. Bansback NJ, Young A, Brennan A. The NICE reappraisal of biologics in 2005: What rheumatologists need to know. Rheumatology 2005;44:3-4.
33. Bansback NJ, Regier DA, Ara R et al. An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis Focus on Tumour Necrosis Factor-α Antagonists. Drugs 2005;65:473-96.
34. National Institute for Clinical Excellence. Guidance on the use etanercept and infliximab for the treatment of rheumatoid arthritis, March 2002. http://www.nice.org.uk/pdf/RA-PDF.pdf
35. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis. 2005;64:iV42-3.
36. Brennan A, Bansback N, Nixon R. Modelling the cost effectiveness of TNF inhibitors in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry, An Independent Report. May 2005. Available at: http://www.shef.ac.uk/scharr/sections/ hods/discussion.html
37. Maetzel A, Tugwell P, Boers M et al. OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
38. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
39. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: Selecting the appropriate approach. J Health Serv Res Policy 2004;9:110-18.
40. Claxton K, Sculpher M, McCabe C et al. Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Econ 2005 Apr;14:339-47.
41. WICE. Retrieved from: http:/www.nice.org.uk/pdf/ Final_protocol_Anti_TNF.pdf
42. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
43. Fries JF, Spitz P, Kraines G, Holman H. Measurement of Patient Outcome in Arthritis. Arthrifis Rheum 1980;23:137-45.
44. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
45. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
46. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
47. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84.
48. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:95-108.
49. Marra CA, Woolcott JC, Kopec JA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
50. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond A, Brazier JE. Using the Health Assessment Questionnaire to estimate preference-based single indices in patients with Rheumatoid Arthritis. [2006] Arthritis Care & Research, In Press.
51. Murray MP. Econometrics. A modern introduction. Boston: Pearson Education Inc., 2006.
52. Greene WH. edn. Econometric analysis, 4th edn. New Jersey: Prentice Hall Inc, 2000.
53. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
54. Scott DL, Garrood T. Quality of life measures: Use and abuse. Baillieres Clin Rheumatol 2000;14:663-87.
55. Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology 2000;39:24-9.
56. Kirwan JR. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 1999;26:720-5.
57. Standard UK life table (Table 16). Available at: www.gad.gov.uk
58. Standard UK life table (Table 17). [WHO Global Burden of Disease programme].
59. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
60. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494-7.
61. British National Formulary. Available at: www.bnf.org/bnf/ (Accessed February 2005).
62. Netten A, Curtis L. Unit Costs of Health and Social Care. Personal Social Services Research Unit, University of Kent, 2002
63. O'Hagan A. Stevenson M and Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation model, (2005). Health Economics, In Press.
64. Deeks JJ, Dinnes J, D'Amico, R et al. International Stroke Trial Coliaborative Group; European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iIi-x, 1-173.
65. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine 2007;26(6):1237-54.
66. Bansback NJ, Young A, Brennan A. The NICE reappraisal of biologics in 2005: What rheumatologists need to know. Rheumatology 2005;44:3-4.